03/23/2026 | Press release | Archived content
If you're looking for another way to ease joint pain with psoriatic arthritis (PsA), adding a weight-loss drug to your medication regimen may help, according to early results of a study involving the obesity medications Zepound (tirzepatide) and Taltz (ixekizumab).
The study, led by Zepbound manufacturer Eli Lilly, found that people living with PsA who also had obesity or were overweight experienced less joint pain when taking Zepbound and Taltz compared with individuals who took Taltz only. After 36 weeks, about 34% of study participants in the combined treatment group vs. 20% in Taltz group had a 50% improvement in the number of tender and swollen joints.
Hear what life with a health condition actually looks like. Now in one app. Built for people living with chronic and rare conditions.
"This is a significant improvement," says Zhanna Mikulik, M.D., a rheumatologist and associate professor in the clinical rheumatology/immunology division of the Ohio State University Wexner Medical Center and College of Medicine in Columbus, OH. (Dr. Mikulik was not involved in the study but reviewed its results.) "This study demonstrated that treatment of obesity improves psoriatic arthritis activity. It's not surprising that weight loss was significantly higher in Taltz plus Zepbound group compared to monotherapy with Taltz alone, in spite of the fact that both groups received counseling on a reduced-calorie diet and increased physical activity."
Managing PsA often involves a combination of medications and healthy lifestyle behaviors, such as exercise to reduce inflammation and improve joint flexibility. Medications to treat PsA range from over-the-counter pain relievers to biologics, which are powerful drugs that target and interfere with the action of proteins and other molecules fueling your pain and inflammation. Biologics, such as Taltz, can be helpful in managing autoimmune conditions such as PsA, plaque psoriasis, and others.
Zepbound is a dual-action injectable medication that functions as both a GLP-1 (glucagon-like peptide-1) receptor agonist and a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. It both suppresses appetite and increases satiety (the feeling of being full). Zepbound is prescribed to adults with obesity to help with weight loss.
Zepbound may be an especially helpful medication for many people with PsA, given that one factor that can complicate PsA treatment is obesity. Research suggests that about one of every two people with PsA also has obesity, a condition that often leads to negative treatment outcomes.
"Obesity worsens PsA by increasing inflammation, pain, and disease activity while also reducing treatment response and creating a vicious cycle where limited mobility leads to further weight gain," explains Wai Lee, M.D., a rheumatologist with the Providence Arthritis Center in Portland, OR, who was not involved with the study but reviewed its results. "Treating obesity directly can reduce PsA burden and improve outcomes, as shown by the improved results when Zepbound was added to Taltz."
Dr. Mikulik adds that obesity is one of the risk factors that can cause the inflammatory skin condition psoriasis to progress to psoriatic arthritis. She also notes that among people with PsA, "obesity is associated with lower rates of remission and poorer responses to treatment."
Several mechanisms probably play a role in the way obesity worsens PsA, Dr. Mikulik says. She explains that fatty tissue contains systemic and local pro-inflammatory properties, which can in turn cause greater joint damage, pain, and stiffness. Carrying excess weight also places increased biomechanical stress on joints, and entheses, the connective tissue which attaches tendons and ligaments to bones. Weight loss, however, may help reduce inflammation levels and disease activity, as well as make physical activity easier.
"Overall, these studies reinforce the importance of treating the whole patient, not only suppressing immune inflammation but also addressing comorbidities, such as obesity, that influence disease severity, treatment response, and long-term outcomes," says rheumatologist Jennifer Schmidt, M.D., with the Medical University of South Carolina, in Charleston, SC. "Additional peer-reviewed data and longer-term follow-up will be helpful in determining how this strategy should ultimately be incorporated into routine rheumatology care."
Taltz and Zepbound each have potential side effects, but the combination isn't likely to trigger any new problems. "No interaction-related safety issues were observed when Taltz and Zepbound were used together," Dr. Lee notes. "Side effects were manageable, and the trial did not identify any significant drug-interaction concerns with the combination."
Both medications can cause injection site redness, along with gastrointestinal problems such as nausea and diarrhea, among other general side effects. Dr. Lee adds that the main side effect with either drug is increased infection risk associated with the immunosuppression effects of Taltz. "I have a few patients who have been treated with Taltz and later Zepbound was added," Dr. Mikulik says. "No additional side effects were noticed. I have a few other patients who take Enbrel, Actemra, or Humira and take Zepbound. Most of them lost a significant amount of weight and feel better."
Dr. Lee also notes that his patients who added the weight-loss drug to their standard PsA treatment had similar results. "Several patients did incidentally note improvement of their arthritis symptoms when the GLP-1 drug was added," Dr. Lee says.
The results of this recent study were part of the TOGETHER-PsA open-label Phase 3b trial. The results have not yet been presented to regulatory authorities, such as the U.S. Food and Drug Administration (FDA), which could approve the combination therapy as a new standard of care for people with psoriatic arthritis who also have obesity." If confirmed, a combination approach may represent a valuable strategy for a subset of PsA patients in whom excess weight contributes to persistent disease activity or reduced treatment response," Dr. Schmidt says.
"It treats two drivers of the disease at once," agree Dr. Lee.Still, Zepbound and other weight-loss drugs aren't right for everyone. People with a history of pancreatitis or severe gastrointestinal disease, for example, may need to avoid the medication. The same is true for people who are pregnant.
If you have PsA and you think you may be a good candidate for Zepbound or another weight-loss medication, talk with your doctor about all the potential risks and benefits. It's important to know that all of these popular medications can be more effective if they are accompanied by a sensible, nutritious diet, regular exercise, and other healthy behaviors.
Study results: Eli Lilly. (2026.) "Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight." https://investor.lilly.com/news-releases/news-release-details/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-0
Obesity: Joint Bone Spine. (2025). "Weighing in on obesity and psoriatic arthritis - Time to move beyond association to robust randomized trials." https://www.sciencedirect.com/science/article/pii/S1297319X25000636